FIELD: medicine, microbiology.
SUBSTANCE: invention concerns biotechnology. It is described bispecific antibody which binds also the factor of blood coagulation IX or the activated factor of blood coagulation IX, and the factor of blood coagulation X, and functionally replaces the factor of blood coagulation VIII or the activated factor of blood coagulation VIII which strengthens enzymatic reaction. The pharmaceutical composition containing the described antibody is revealed. The present invention can be used as an alternative agent for functional replacement of cofactor which strengthens enzymatic reaction.
EFFECT: creation of bispecific antibody which can replace functional proteins, strengthens enzymatic reaction.
14 cl, 18 dwg, 37 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTISPECIFIC ANTIGEN-BINDING MOLECULE, POSSESSING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII | 2013 |
|
RU2534347C1 |
| MULTISPECIFIC ANTIGEN-BINDING MOLECULE THAT HAS ALTERNATE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII | 2013 |
|
RU2534564C1 |
| MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATE FUNCTION TO BLOOD COAGULATION FACTOR VIII FUNCTION | 2011 |
|
RU2620071C2 |
| BISPECIFIC ANTIBODY HAVING HIGH ACTIVITY, ALTERNATIVE FUNCTION OF COFACTOR FVIII | 2017 |
|
RU2821642C2 |
| ANTIBODY WHICH IS CAPABLE OF NEUTRALIZING A SUBSTANCE HAVING AN ACTIVITY OF AN ALTERNATIVE COAGULATION FACTOR FUNCTION VIII (FVIII) | 2015 |
|
RU2737145C2 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2739946C2 |
| PHARMACEUTICAL COMPOSITION FOR PANCREATIC CANCER TREATMENT AND/OR PREVENTION | 2012 |
|
RU2630638C2 |
| METHOD FOR MEASURING REACTIVITY OF FVIII | 2015 |
|
RU2752595C2 |
| INHIBITORY ANTI-FACTOR XII/XIIa MONOCLONAL ANTIBODIES AND THEIR USE | 2012 |
|
RU2660370C2 |
